Details of the Drug Reposition

General Information of This Drug (ID: DM0SRAN)

Drug Name
CC-122   DM0SRAN
Synonyms
cc-122; 1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
7 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Recurrent glioblastoma DISHYPKS 2A00.00 Phase 1 [1]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [2]
Lymphoma DISN6V4S 2A80-2A86 Phase 1 [3]
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1 [3]
Chronic lymphocytic leukaemia DISEXWC3 2A82.0 Phase 1 [3]
Multiple myeloma DISEWP9B 2A83 Phase 1 [3]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 1 [3]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01421524) Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)